Vokietija – Mokslinių tyrimų ir taikomosios veiklos paslaugos bei su jomis susijusios konsultacinės paslaugos – Toxicity study in naïve mice
Vokietija – Mokslinių tyrimų ir taikomosios veiklos paslaugos bei su jomis susijusios konsultacinės paslaugos – Toxicity study in naïve mice
I dalis: Perkančioji organizacija
I.1) Pavadinimas ir adresai:
Oficialus
pavadinimas: BiconY Therapeutics GmbH
Adresas: Lagerhofstraße 4
Miestas: Leipzig
Pašto
kodas: 04103
Šalis: Vokietija
Asmuo
ryšiams:
El-paštas: bicony.tenderprocedure@fgvw.de
Interneto adresas (-ai):
II dalis: Objektas
II.1.1) Pavadinimas:
Toxicity study in naïve mice
Nuorodos numeris: BiconY 01/2025
II.1.2) Pagrindinis BVPŽ kodas:
73000000
Mokslinių tyrimų ir taikomosios veiklos paslaugos bei su jomis susijusios konsultacinės paslaugos
II.1.3) Sutarties tipas:
Kita
II.1.4) Trumpas aprašymas:
The Federal Agency for Disruptive Innovation - SPRIND GmbH ("SPRIND") - aims to cre-ate new disruptive innovations from Germany. That means products, services and sys-tems that make all our lives noticeably and sustainably better. To achieve this, SPRIND brings together new thinkers from science and business, people with outstanding ideas, special expertise, and passion. Hence, SPRIND provides an entrepreneurial environment that turns ideas into reality. The objective of BiconY Therapeutics GmbH, a SPRIND subsidiary, is the development of a bispecific antibody combination for the treatment of solid tumours. The combination con-sists of proprietary, bispecific CD3 anti-bodies (bsAbCD3) and bispecific CD28 co-stimulators (BiCos), which, when used together, significantly im-prove the specificity, sus-tainability, and efficiency of a T cell recruitment and thus the immune response against tumour cells. The aim of the research and development activities is to provide proof of concept for the effect of bispecific antibody therapy in the form of two phase I/IIa clinical trials. For the IND application at Paul Ehrlich Institute (Germany) we have to show safety of our molecules in animal models. Following extensive discussions and thorough analyses, the PEI has granted approval for a comprehensive toxicological study of our lead candidate in mice. Therefore, we are looking for a service provider to support us regarding pharmaco-toxicological studies
II.2) Aprašymas:
II.2.1) Kitas (-i) šio pirkimo BVPŽ kodas (-ai):
73000000 Mokslinių tyrimų ir taikomosios veiklos paslaugos bei su jomis susijusios konsultacinės paslaugos